I asked Gemini. See the response below.

Major news broke this week regarding a significant shift in FDA policy that has immediate, positive implications for ImmunityBio (IBRX) and its pursuit of a broader label for ANKTIVA.

​Here is a summary of the situation as of February 20, 2026:

​The FDA Policy Shift: "One Pivotal Trial" Standard

​On February 18, 2026, the FDA announced a landmark change to its drug approval process, effectively ending the "two-trial dogma."

• ​The Change: The FDA will now allow a single adequate and well-controlled clinical trial (supported by confirmatory evidence) to serve as the basis for drug approval, rather than requiring two separate pivotal studies.
• ​The Intent: This move is designed to reduce development costs (estimated at $30M–$150M per trial) and accelerate the delivery of therapies to market.
• ​Oncology Impact: While oncology has often enjoyed some flexibility, this formalizes the standard, shifting the focus from the quantity of trials to the magnitude of effect and quality of data within a single study.

​Impact on ImmunityBio & Papillary Bladder Cancer

​This news is a major tailwind for ImmunityBio’s supplemental Biologics License Application (sBLA) for BCG-unresponsive papillary-only NMIBC.

​1. Validating the "Single-Arm" Approach

​Previously, ImmunityBio faced a "Refuse to File" (RTF) letter in May 2025 because the FDA questioned the use of single-arm, non-randomized data for the papillary-only population (Cohort B of the QUILT-3.032 trial).

• ​The Conflict: The FDA had approved ANKTIVA for CIS (Carcinoma in Situ) using single-arm data but initially insisted on a randomized trial for papillary disease because it is surgically resectable.
• ​The Resolution: Following a Type B meeting in January 2026, the FDA signaled a path forward using the existing single-arm data. This week's broader policy shift confirms that the Agency is moving away from rigid requirements for multiple or randomized trials when the clinical benefit is clear.

​2. The Strength of the Papillary Data

​ImmunityBio’s recently submitted data for papillary-only patients is robust, which fits the FDA's new "quality over quantity" focus:

• ​96% Disease-Specific Survival at 36 months.
• ​82% Cystectomy-Free Survival (avoidance of bladder removal) at three years.
• ​No New Trials Needed: ImmunityBio confirmed that their resubmission path does not require the initiation of any new clinical trials, saving years of development time.

​3. Global Momentum

​The FDA’s shift coincides with major international wins for ImmunityBio:

• ​EU Approval: On February 18, 2026, the European Commission granted marketing authorization for ANKTIVA based on the same single-arm QUILT trial.
• ​Saudi Arabia: The Saudi FDA also granted approval this month for ANKTIVA in both bladder and lung cancer.